JP2013504551A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504551A5 JP2013504551A5 JP2012528448A JP2012528448A JP2013504551A5 JP 2013504551 A5 JP2013504551 A5 JP 2013504551A5 JP 2012528448 A JP2012528448 A JP 2012528448A JP 2012528448 A JP2012528448 A JP 2012528448A JP 2013504551 A5 JP2013504551 A5 JP 2013504551A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- ring system
- alkenyl
- medicament according
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 11
- -1 aminocarbonyloxy Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000002345 steroid group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000003003 spiro group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 3
- 229940124530 sulfonamide Drugs 0.000 claims 3
- 150000003456 sulfonamides Chemical class 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000006323 alkenyl amino group Chemical group 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000006319 alkynyl amino group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 150000001540 azides Chemical class 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000005016 hydroxyalkynyl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 150000002923 oximes Chemical class 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 2
- FMOHTQBFGJULLE-HNFJNZPISA-N (3s,8r,9s,10r,13s,14s,17r)-3'-(hydroxymethyl)-10,13-dimethylspiro[1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-17,2'-oxirane]-3-ol Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C[C@@]11OC1CO FMOHTQBFGJULLE-HNFJNZPISA-N 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000005014 aminoalkynyl group Chemical group 0.000 claims 1
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 125000005335 azido alkyl group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 150000002926 oxygen Chemical class 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0916020A GB0916020D0 (en) | 2009-09-11 | 2009-09-11 | Use of steroid compounds |
| GB0916020.1 | 2009-09-11 | ||
| GB1009342.5 | 2010-06-03 | ||
| GBGB1009342.5A GB201009342D0 (en) | 2010-06-03 | 2010-06-03 | Use of steroid compounds |
| PCT/GB2010/001727 WO2011030116A1 (en) | 2009-09-11 | 2010-09-13 | Use of steroid compounds for inflammatory and autoimmune disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013504551A JP2013504551A (ja) | 2013-02-07 |
| JP2013504551A5 true JP2013504551A5 (enExample) | 2013-11-07 |
| JP5826750B2 JP5826750B2 (ja) | 2015-12-02 |
Family
ID=43063384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528448A Expired - Fee Related JP5826750B2 (ja) | 2009-09-11 | 2010-09-13 | 炎症性疾患および自己免疫疾患へのステロイド化合物の使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120225852A1 (enExample) |
| EP (1) | EP2475369A1 (enExample) |
| JP (1) | JP5826750B2 (enExample) |
| KR (1) | KR20120068026A (enExample) |
| CN (1) | CN102711769A (enExample) |
| AU (1) | AU2010293960B2 (enExample) |
| BR (1) | BR112012008352A2 (enExample) |
| CA (1) | CA2773600A1 (enExample) |
| EA (1) | EA021840B1 (enExample) |
| IL (1) | IL218503A0 (enExample) |
| IN (1) | IN2012DN02613A (enExample) |
| MX (1) | MX2012002834A (enExample) |
| SG (1) | SG179049A1 (enExample) |
| WO (1) | WO2011030116A1 (enExample) |
| ZA (1) | ZA201202022B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104027302B (zh) * | 2013-03-07 | 2019-04-05 | 中国医药工业研究总院 | 17α-乙炔基雄甾-5-烯-3β,7β,17β-三醇眼用制剂 |
| WO2017218824A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| WO2019152808A1 (en) * | 2018-02-01 | 2019-08-08 | Yale University | Compositions and methods for inhibition of nuclear-penetrating antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3365475A (en) | 1966-07-22 | 1968-01-23 | Merck & Co Inc | Process for the preparation of 17alpha-(3'-hydroxy-propyl)-4-androstene-3beta, 17beta-diol |
| DE2349023A1 (de) * | 1973-09-26 | 1975-04-10 | Schering Ag | Neue d-homo-steroide |
| DE2349022A1 (de) * | 1973-09-26 | 1975-04-10 | Schering Ag | Neue d-homo-steroide |
| US4054563A (en) | 1975-04-25 | 1977-10-18 | Ciba-Geigy Corporation | Process for the manufacture of spiro compounds of the steroid series |
| US4243586A (en) * | 1980-01-18 | 1981-01-06 | E. R. Squibb & Sons, Inc. | Steroidal-17-spiro-dihydrofuranones |
| DE3416112A1 (de) * | 1984-04-30 | 1985-10-31 | Roecar Holdings (Netherlands Antilles) N.V., Willemstad, Curacao, Niederländische Antillen | Verwendung von sterolinen und spiroketalinen als lipoxygenaseregulatoren |
| FR2596395B1 (fr) * | 1986-03-26 | 1989-05-26 | Roussel Uclaf | Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| US5846963A (en) * | 1995-06-07 | 1998-12-08 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US20060004076A1 (en) * | 2004-06-30 | 2006-01-05 | Inflabloc Pharmaceuticals, Inc. | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation |
| WO2007025780A2 (en) * | 2005-09-02 | 2007-03-08 | Recordati Ireland Limited | Aldosterone receptor antagonists |
| WO2007103162A2 (en) * | 2006-03-01 | 2007-09-13 | Samaritan Pharmaceuticals, Inc. | Structure based drug design of steroidogenesis inhibitors |
| GB0711948D0 (en) * | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
-
2010
- 2010-09-13 WO PCT/GB2010/001727 patent/WO2011030116A1/en not_active Ceased
- 2010-09-13 JP JP2012528448A patent/JP5826750B2/ja not_active Expired - Fee Related
- 2010-09-13 MX MX2012002834A patent/MX2012002834A/es active IP Right Grant
- 2010-09-13 SG SG2012016416A patent/SG179049A1/en unknown
- 2010-09-13 US US13/395,381 patent/US20120225852A1/en not_active Abandoned
- 2010-09-13 BR BR112012008352A patent/BR112012008352A2/pt not_active IP Right Cessation
- 2010-09-13 EP EP10757115A patent/EP2475369A1/en not_active Withdrawn
- 2010-09-13 AU AU2010293960A patent/AU2010293960B2/en not_active Ceased
- 2010-09-13 CN CN2010800404946A patent/CN102711769A/zh active Pending
- 2010-09-13 KR KR1020127009258A patent/KR20120068026A/ko not_active Ceased
- 2010-09-13 IN IN2613DEN2012 patent/IN2012DN02613A/en unknown
- 2010-09-13 CA CA2773600A patent/CA2773600A1/en not_active Abandoned
- 2010-09-13 EA EA201270399A patent/EA021840B1/ru not_active IP Right Cessation
-
2012
- 2012-03-06 IL IL218503A patent/IL218503A0/en unknown
- 2012-03-19 ZA ZA2012/02022A patent/ZA201202022B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3424978B2 (ja) | 単量体胆汁酸誘導体、その調製方法およびそれを含有する低脂血剤 | |
| US9096640B2 (en) | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-methylene oxyalkylene aryl derivatives, process for preparation thereof, and use thereof for treatment of diseases | |
| US20190083473A1 (en) | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
| TW200944540A (en) | C20-C21 substituted glucocorticoid receptor agonists | |
| AU676198B2 (en) | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants | |
| TWI284646B (en) | Novel anti-inflammatory androstane derivatives | |
| MXPA03001097A (es) | Derivado de 17.beta.-carbotioato 17.alfa.-arilcarboniloxiloxi androstano como agentes inflamatorios. | |
| CN105189503A (zh) | 人免疫缺陷病毒复制的抑制剂 | |
| JP2013504551A5 (enExample) | ||
| TW201249839A (en) | Pyridyl aminopyridines as Syk inhibitors | |
| MXPA06000442A (es) | Compuesto glucocorticoide especifico que tiene actividad anti-inflamatoria. | |
| RU2005103226A (ru) | Новые соединения, составы и способы лечения воспалительных заболеваний и состояний | |
| EP2813509B1 (en) | 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinoline derivatives | |
| JP2000501732A (ja) | 抗炎症薬として有用な新規ステロイドナイトライト／ナイトレートエステル誘導体 | |
| JP2009524649A (ja) | 新規１１β−ヒドロキシアンドロスタ−４−エン−３−オン | |
| EP2187888A2 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| CN101472922A (zh) | 新型苯并噻嗪酮衍生物及其作为抗菌剂的应用 | |
| US20140349968A1 (en) | Compositions and Methods for Treating Cancer | |
| AU672669B2 (en) | New steroids | |
| AU2018386464B2 (en) | Small molecule modulators of the BTB domain of Keap1 | |
| WO2021220061A2 (en) | Heterodimer compositions and methods for the treatment of ocular disorders | |
| TW201111392A (en) | Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof | |
| IL292548A (en) | Processes for the preparation of s1p-receptor modulator | |
| JP5826750B2 (ja) | 炎症性疾患および自己免疫疾患へのステロイド化合物の使用 | |
| JP2019532071A (ja) | 非常に強力な糖質コルチコイドの構造およびデザインのための機構 |